ORPHAN EXCLUSIVITY FOR SIMILAR BIOTECH PROTEIN DRUGS: establishment of an FDA expert panel on the issue is recommended in a Feb 15 joint letter from 22 molecular biologists to FDA Acting Commissioner Benson